Investing.com - Kronos Bio (NASDAQ: KRON) reported first quarter EPS of $-0.500, $0.06 worse than the analyst estimate of $-0.445. Revenue for the quarter came in at $2.52M versus the consensus estimate of $1.38M.
Kronos Bio's stock price closed at $1.05. It is down -0.940% in the last 3 months and down -41.990% in the last 12 months.
Kronos Bio saw positive EPS revisions and negative EPS revisions in the last 90 days. See Kronos Bio's stock price’s past reactions to earnings here.
According to InvestingPro, Kronos Bio's Financial Health score is "fair performance".
Check out Kronos Bio's recent earnings performance, and Kronos Bio's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar